BJMO - volume 18, issue 8, december 2024
P. Vanclooster MD
SUMMARY
While ESMO 2024 once again did not yield a phase III trial for brain tumours, it presented intriguing findings from early-phase clinical trials and translational studies. We highlight three of the most significant and promising trials related to brain tumours discussed at the conference, particularly focusing on IDH-mutated tumours, glioblastoma, and novel immunotherapy strategies.
(BELG J MED ONCOL 2024;18(8):337–340)
Read more
Top
